GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (STU:4QG) » Definitions » Institutional Ownership

PCI Biotech Holding ASA (STU:4QG) Institutional Ownership : 0.55% (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PCI Biotech Holding ASA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PCI Biotech Holding ASA's institutional ownership is 0.55%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PCI Biotech Holding ASA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PCI Biotech Holding ASA's Float Percentage Of Total Shares Outstanding is 0.00%.


PCI Biotech Holding ASA Institutional Ownership Historical Data

The historical data trend for PCI Biotech Holding ASA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Institutional Ownership Chart

PCI Biotech Holding ASA Historical Data

The historical data trend for PCI Biotech Holding ASA can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.56 0.56 0.56 0.55 0.55 0.55 0.55 0.55 0.55 0.55

PCI Biotech Holding ASA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


PCI Biotech Holding ASA (STU:4QG) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (STU:4QG) Headlines

No Headlines